Colorectal cancer ranks as the second leading cause of cancer-related fatalities in the United States. The American Cancer Society predicts over 55,000 deaths from this disease in the current year. Alarmingly, rates among adults under 50 are increasing, while treatment still heavily depends on chemotherapy, which often entails severe side effects.
Spencer’s Journey: From Diagnosis to Hope
One young father, Spencer, has become a trailblazer in a groundbreaking clinical trial. At just 27 years old, he faced the daunting diagnosis of colorectal cancer while cherishing a life with his wife, CarleyAnn, and their daughter Madison. Spencer experienced symptoms for over a year but was frequently dismissed by doctors who attributed them to hemorrhoids.
His condition escalated, leading to surgery that removed his colon. While it seemed effective initially, two years later, he learned he had developed 13 tumors in his lungs. “There was no plan. It was just chemo and radiation and two years to live,” he recalled. The thought of leaving his family haunted him.
Exploring Alternative Treatments
Standard chemotherapy treatment terrified Spencer due to its lasting side effects. He viewed it as a last resort rather than a primary option. Dr. Nicholas DeVito, an oncologist at Duke Health, understood his concerns and opted for a different approach. Instead of immediately resorting to chemotherapy, they began with immunotherapy, employing two drugs designed to activate Spencer’s immune system against the cancer.
Transformative Results and Future Implications
The trial involved a rigorous routine for Spencer and his family. Every two weeks, they drove four hours from their home to Duke University for treatment. Remarkably, the results were life-altering. “He has had a near-complete response. Most of his cancer is gone,” Dr. DeVito described. This new approach holds promise not just for Spencer, but for many patients facing similar battles.
Spencer is now back home, cherishing time with his family and embracing a future he once feared was lost. He attributes his recovery not only to medical advances but also to his faith. “Not long after that is when God really showed up in my life. It’s been uphill ever since,” he expressed.
Broader Impacts on Cancer Treatment
Current research indicates that some patients using immunotherapy as a first-line treatment have experienced tumor reductions exceeding 30%. Others have managed to stabilize their cancer, postponing the need for chemotherapy. These findings could pave the way for more extensive trials across additional medical facilities, potentially transforming how colorectal cancer is treated in the future.
- Over 55,000 colorectal cancer deaths projected in 2023.
- Immunotherapy shows promise as a primary treatment option.
- Patients have reported significant tumor reduction without chemotherapy.
